Topics
March 2012 | Perspectives: from The Editors Of New Retina Md
The Sunshine Act's Intimidation Factor
Will the noble objectives of this law set up a roadblock to innovation?
Richard S. Kaiser, MD, and Jonathan L. Prenner, MD
November 20, 2026
Opus Genetics Doses First Patient in Phase 1/2 Gene Therapy Trial for RDH12-Associated Leber Congenital Amaurosis
November 19, 2026
FDA Grants Rare Disease Evidence Principles Designation to NanoRetinal’s NAR-001 for Inherited Retinal Dystrophy
Foundation Fighting Blindness Receives $1 Million Commitment to Advance Gene-Agnostic Retinal Disease Therapies
November 17, 2026
MacuMira Receives CE Mark Certification for Retinal Microcurrent Stimulation Device to Treat Dry AMD
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Supported by Zeiss
Free Print Subscription
Email Newsletter
Conference Calendar